Drugs / TEIPP24
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05898763 | Sep 2021 → Apr 2024 | non-small cell lung carcinoma | Erasmus Medical Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TEIPP24 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05898763 ↗ |
| Modality | Vaccine | “therapeutic LRPAP1 synthetic long peptide (LRPAP7-30V-SLP) vaccine (TEIPP24)” NCT05898763 ↗ |
| Route | Subcutaneous | “The SC route of administration of TEIPP24 vaccine” NCT05898763 ↗ |